The metabolic syndrome and cerebrovascular disease: suspicion and evidence (Q36986380)

17 August 2017

1 reference

title

The metabolic syndrome and cerebrovascular disease: suspicion and evidence (English)

1 reference

17 August 2017

1 reference

cerebrovascular disease

1 reference

Antonio Gil-Núñez

1

1 reference

17 August 2017

publication date

1 November 2007

1 reference

17 August 2017

published in

Cerebrovascular Diseases

1 reference

17 August 2017

volume

24 Suppl 1

1 reference

17 August 2017

page(s)

64-75

1 reference

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

17 August 2017

cites work

1 reference

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

21 January 2018

1 reference

Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study

21 January 2018

1 reference

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

21 January 2018

1 reference

A comparison of the prevalence of the metabolic syndrome using two proposed definitions

21 January 2018

1 reference

Increasing prevalence of the metabolic syndrome among u.s. Adults.

21 January 2018

1 reference

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults

21 January 2018

1 reference

The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study

21 January 2018

1 reference

Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

Metabolic syndrome as an independent risk factor of silent brain infarction in healthy people.

21 January 2018

1 reference

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

21 January 2018

1 reference

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

Long term risks of stroke, myocardial infarction, and vascular death in "low risk" patients with a non-recent transient ischaemic attack

21 January 2018

1 reference

Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events

21 January 2018

1 reference

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

21 January 2018

1 reference

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

21 January 2018

1 reference

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

Aspirin for the primary prevention of cardiovascular events: recommendation and rationale

21 January 2018

1 reference

Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial

21 January 2018

1 reference

Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus

21 January 2018

1 reference

Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies

21 January 2018

1 reference

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services

21 January 2018

1 reference

The Metabolic Syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000107380

1 reference

17 August 2017

1 reference